|
Mesothelioma and Lung Cancer News - Return to Menu
Another reason to enjoy pecans
By Chad Boutin
Purdue University
WEST LAFAYETTE, Ind. -- The form of vitamin E found in many plant seeds -- but not in most vitamin pills and supplements -- might halt the growth of prostate and lung cancer cells, according to a Purdue University study.
A team led by Qing Jiang (her name is pronounced "ching zhang") has found that gamma-tocopherol, which occurs naturally in walnuts, pecans, sesame seeds, and in corn and sesame oils, inhibits the proliferation of lab-cultured human prostate and lung cancer cells.
The vitamin's presence interrupts the synthesis of certain fatty molecules called sphingolipids, important components of cell membranes. However, the gamma-tocopherol leaves healthy human prostate cells unaffected, which could give it value as an anticancer agent.
"This is the first time gamma-tocopherol (the form of vitamin E studied) has been shown to induce death in lab-grown human cancer cells while leaving healthy cells alone," said Jiang, who is an assistant professor of foods and nutrition in the College of Consumer and Family Sciences.
"This could be wonderful news for cancer patients if the effect can be reproduced in animal models. But because most nutritional supplements contain only alpha-tocopherol, a different form of vitamin E that alone does not have these anticancer properties, it may be better to supplement the diet with mixed forms of vitamin E. The study at Purdue shows that the anticancer effect is enhanced when mixed forms are used."
Jiang's research appeared Dec. 13 in the online edition of the scientific journal, "Proceedings of the National Academy of Sciences." She co-authored the paper with Jeffrey Wong, Henrik Fyrst, Julie D. Saba and Bruce N. Ames of the Children's Hospital Oakland Research Institute in Oakland, Calif.
Scientists have been studying vitamin E for more than three-quarters of a century, but most efforts have focused largely on alpha-tocopherol, one of eight known forms in the vitamin's family. Alpha-tocopherol was found early on to have the most beneficial effects on laboratory animals fed diets deficient in vitamin E, and also is the major form found in body tissues. For these reasons, it has been nearly the only form of the vitamin to be included in most manufactured nutritional supplements.
"Since then, alpha-tocopherol has justifiably earned a good reputation as an antioxidant, which helps to fight against damage caused by unwanted free radicals," Jiang said. (Free radicals that cause cell damage occur in bodies as they age.)
"But its familiarity has perhaps attracted research away from the other seven forms of vitamin E, and since gamma-tocopherol is the vitamin's most commonly occurring natural form in the American diet, I grew interested in it a few years ago."
In 2000, another study by Jiang and colleagues found that gamma-tocopherol inhibits inflammation, which had already been implicated in cancer development. They theorized that it might retard the progress of cancer and cardiovascular disease, and to test their hypothesis they exposed cultures of cancerous prostate and lung cells to the vitamin. Normal prostate epithelial cells were used as a control group.
"We discovered that as we increased the quantity of gamma-tocopherol, the cancer cells grew more slowly," Jiang said. "But the normal prostate cells were not affected and grew normally. This could indicate that this form of the vitamin could be used to target lung and prostate cancer cells without the damaging side effects of chemotherapy."
The study also revealed that gamma-tocopherol caused cell death by interrupting sphingolipid synthesis (fatty molecules part of cell membranes).
"This is also a novel discovery," Jiang said. "Although there have been prior indications that some form of vitamin E may cause cell death in some mouse cell lines, we are the first to provide a mechanism for such an effect."
Gamma-tocopherol, though rarely available in vitamin pills, is nevertheless found in abundance in the typical American diet. Many nuts are rich in it, including walnuts and pecans, as are corn oil and sesame oil.
Though Jiang said she would be cautious about using food sources to slow prostate or lung cancer's progress in humans, she said that high-risk groups such as older men could benefit from supplementation -- if carried out with prudence.
"Foods rich in gamma-tocopherol (a particular form of vitamin E) are also rich in fats, and some products bring other health hazards as well," she said. "Corn oil, for example, is rich in linolic acid, which has been shown to promote certain types of cancer in some studies. But sesame seeds and pecans seem to be good, all-around diet choices."
Jiang said the next step for her research team would be testing the effect of gamma-tocopherol and mixed forms of vitamin E on animal cancers.
"Although this discovery is promising, we do not yet know whether gamma-tocopherol has any effect on cancer in living creatures," she said. "We hope that future research not only will clarify whether gamma-tocopherol could have applications in human cancer treatment, but also will show how we might supplement the body with the vitamin to prevent cancer from developing in the first place. These questions will continue to direct our work."
This research was funded in part by the National Institutes of Health. Web site for the online paper: www.pnas.org/papbyrecent.shtml.
Publication Date: 01-05-2005
Judge backs Babcock & Wilcox plan
By Jim Jelter, MarketWatch
SAN FRANCISCO (MarketWatch) - 12/29/2005 - A federal judge backed a revised reorganization plan for McDermott International Inc.'s subsidiary Babcock & Wilcox Co., a step toward exiting bankruptcy nearly six years after asbestos-related lawsuits sent it into Chapter 11 protection.
New Orleans-based McDermott (MDR: McDermott International, Inc. said Thursday that following a full review, Judge Jerry Brown at the U.S. Bankruptcy Court of the Eastern District of Louisiana recommended on Wednesday that the plan go forward.
The plan now includes a $7.5 million settlement with Citgo Petroleum Corp., PDV Midwest Refining, LLC and other insurers that had objected to an earlier reorganization proposal.
It also requires that plaintiffs in the lawsuit agree to limit Babcock & Wilcox's maximum uninsured exposure to $50 million and drop further claims against its parent, energy-services giant McDermott.
With a Feb. 22 deadline, the plan now goes to Judge Sarah Vance at the U.S. District Court for the Eastern District of Louisiana, who will review Judge Brown's findings and confirm or reject the plan, which also needs to secure exit financing and approval from McDermott's shareholders.
Babcock & Wilcox, which makes industrial boilers and power generation systems, filed for bankruptcy in 2000. The move prompted McDermott to sever Babcock & Wilcox from the parent company's financial statements and write off its investment in the subsidiary, a process it completed in 2002.
McDermott shares ended the thinly-traded session with a 0.5% loss at $42.30, down from an early intraday high of $43.25.
|
